Clinical Trials Browser

Interventional × Valganciclovir × Head & Neck × Clear all

NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05166577 2025-03-12

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Phase 1 Terminated

26 enrolled 23 charts

Nasopharyngeal Carcinoma

NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

Phase 2 Withdrawn

GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

NCT02761291 2016-05-16

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1 Unknown

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence, Epstein-Barr Virus Infections, Multiple Acyl Coenzyme A Dehydrogenase Deficiency